GlassScriptPhysician profile
David Alboukrek
NPI 1255434031
$10,612.88
in general payments reported to CMS, 2019-2025
31 companies · $2,525 in 2025
The $2,525 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,804 · 2020: $358 · 2021: $1,055 · 2022: $1,734 · 2023: $1,500 · 2024: $1,636 · 2025: $2,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,496 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,496.27 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,280.31 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,622.85 | 2019-2025 | Tremfya, Remicade, Simponi |
| Amgen INC. | $1,308.41 | 2019-2025 | Evenity, Prolia, Prolia |
| E.R. Squibb & Sons, L.L.C. | $763.45 | 2019-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $706.23 | 2019-2025 | |
| Ucb, INC. | $581.96 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $528.25 | 2019-2025 | |
| Glaxosmithkline, LLC. | $448.49 | 2019-2025 | Benlysta, Nucala |
| Radius Health, INC. | $429.38 | 2019-2025 | Tymlos |
| Horizon Therapeutics Plc | $259.09 | 2019-2023 | Krystexxa |
| Alvogen INC | $250.20 | 2021-2025 | Teriparatide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.73 | 2019-2025 | Ofev, Cyltezo |
| Mallinckrodt Hospital Products INC. | $175.99 | 2020-2025 | Acthar |
| Sanofi-Aventis U.S. LLC | $132.39 | 2019 | |
| Genentech USA, INC. | $121.30 | 2022-2024 | Actemra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $119.46 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $116.31 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $115.27 | 2021-2024 | Saphnelo |
| Sobi, INC | $110.51 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $46.80 | 2019-2020 | |
| Lilly USA, LLC | $45.93 | 2020-2022 | |
| Fresenius Kabi USA, LLC | $39.39 | 2023 | Idacio |
| Actelion Pharmaceuticals US, INC. | $38.57 | 2023 | Opsumit |
| Ani Pharmaceuticals, INC. | $34.01 | 2024 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $26.27 | 2019 | |
| Organon LLC | $25.61 | 2022-2024 | |
| Celgene Corporation | $23.85 | 2019 | |
| Aurinia Pharma U.S., INC. | $21.07 | 2024 | Lupkynis |
| Ferring Pharmaceuticals INC. | $18.46 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $16.24 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Alboukrek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.